Medical News, 2023 IVRA International Cancer Treatment Medical Sharing Conference held in April

International Conference on Medical Sharing to Overcome COVID-19 Pandemic (September 2021)

IVRA International Medical Sharing Conference (2022.6)

South Chungcheong Province Governor Yang Seung-mo giving a congratulatory speech at the IVRA International Conference

IVRA 2021 Year-End General Meeting

The ‘2023 IVRA International Cancer Treatment Medical Sharing Conference’ will be held on April 28-29 at Maria Hall, Seoul St. Mary’s Hospital, Catholic University of Korea. This event, attended by domestic and foreign medical scholars, is hosted by the International Virus Research Association (IVRA) Organizing Committee and the Korean Society of Thermal Medicine and hosted by AdipoLABs Co., Ltd.

In 2021, IVRA captured the attention of domestic and foreign medical staff when the treatment case of a patient who received intensive hyperthermia treatment at the Seosan Medical Center COVID-19 Treatment Center in South Chungcheong Province became known. At that time, medical staff and IVRA members collaborated to form an association for COVID-19 treatment. Afterwards, Dr. Yoo Seung-mo of Yesan Myeongji Hospital in South Chungcheong Province, Dr. Lee Kang-hyeon of Wonju Severance Christian Hospital, Director Kim Seon-man of Suwon Amirang Clinic, and Han Sung-ho, CEO of AdipoLABs Co., Ltd. participated as organizers, and IVRA, with domestic and foreign medical staff joining as members, was established as an international medical institution in September of that year. At the conference of September, a case presentation on the effects of hyperthermia and immunotherapy on COVID-19 patients in 2021 and 2022, which received a great response from domestic and foreign medical staff wad delivered.

Chungcheongnam-do Seosan Medical Center COVID-19 patient REMISSION 1℃ treatment procedure

Chungcheongnam-do Seosan Medical Center REMISSION 1℃ donation ceremony

IVRA focuses on cancer treatment research

In June 2022, IVRA was brought upon based on the results achieved through hyperthermia and immunotherapy that has set a new direction of research focusing on cancer treatment. That has been a humanity's long-cherished wish. The ‘International Medical Seminar for Presenting Protocols for Virus, Cancer, and Pain Management’ held at COEX in the same year received a great response, with approximately 80 foreign dignitaries and 200 domestic and foreign officials attending. For another conference to be held in April based on the achievements so far, the IVRA organizing committee is accepting cancer treatment cases using the high-frequency hyperthermia cancer treatment device REMISSION 1℃, which is being used in various countries. Medical staff from various countries, including Malaysia, which proposed cooperation for joint research, are expressing their intention to actively participate.

Romanian Minister of the Interior Arafat attending IVRA

AdipoLABs Healthcare opening ceremony in Malaysia

Research cooperation MOU signing ceremony with Cyberjaya University, Malaysia

Donation of REMISSION 1℃ to Cancer Treatment Research Center (Dr. HO) at UMMC University in Malaysia

Signed a research MOU with a Malaysian university

AdipoLABs signed an MOU with Malaysia's Cyberjaya University on February 26 to strengthen cooperation in academic and research fields. Cyberjaya is a science complex located in Putra Jaya, the administrative city of Malaysia, and is called ‘Malaysia’s Silicon Valley’. AdipoLABs, which has a branch in Malaysia, signed an MOU with its partner, Cyberjaya University, for joint clinical research to advance into ASEAN.

The business agreement ceremony was attended by Korea AdipoLABs CEO Han Sung-ho, team leader Han Ye-eun, Dr. Yoo Seung-mo of Yesan Myeongji Hospital, Director Woo Ja-sang of Yonsei King's Hospital, and Yoo Seong-cheol, team leader of Red & Blue. At the University of Cyberjaya, Vice Chancellor Zabidi Azhar Mohd Hussin and research professors participated to strengthen academic and research cooperation based on pain treatment and cancer treatment research and to pursue various collaborations. AdipoLABs anticipated a fruitful collaboration in near future. 

Han Sung-ho, CEO of AdipoLABs, said, “The expansion of AdipoLABs Healthcare, a Malaysian partner, the strengthening of cooperation with researchers at Cyberjaya University through the MOU, and the REMISSION 1℃ introduced at this international academic conference will help cancer patients suffering around the world. I hope it becomes a beacon of hope,” he said.

2022 IVRA International Medical Sharing Conference Dinner Commemorative Photo

AdipoLABs CEO Han Sung-ho and Cambodian Minister of Agriculture and Forestry

Cambodian Minister of Agriculture (Sakhon Veng) and State Council members

The 2023 IVRA International Cancer Treatment Medical Sharing Conference will be held with medical staff from over 20 countries, the Catholic University of Korea's Seoul St. Mary's Hospital Advanced Medical Research Institute, Wonju Severance Christian Hospital, Amirang Medical Center, Daejeon University Seoul Oriental Medicine Hospital, Dongseo Cancer Center, Chihyu Oriental Medicine Hospital, and Biosin. Organizations such as Korea Co., Ltd., Red & Blue, Korean Society of Thermal Medicine, Korean Society of Balance Medicine, and Korean Emergency Medicine Association are scheduled to participate.

Cancer patients, their families, and the general public who are interested in new cancer treatment cases can also apply for the two-day seminar on high-frequency hyperthermia cancer treatment cases and pain treatment if they wish to participate. In particular, on the 28th, with cancer patients, their families, and related medical staff in attendance, domestic and foreign cancer treatment experts plan to present cancer treatment clinical results focusing on vivid cases through REMISSION 1℃.

At the conference on the 29th, IVRA Chairman Dr. Yoo Seung-mo, Amirang Clinic Director Dr. Kim Seon-man, India's Dr. Nagraj, Dr. Damodara, Dr. Jang Hong-seok of Seoul St. Mary's Hospital of the Catholic University of Korea, China's Professor Wu Zibing, Malaysian Dr. Ho, and Korean Society of Thermal Medicine President Choi Il-bong will present cases of REMISSION 1℃ treatment from each country and hold related seminars. In the future, AdipoLABs announced that it will sign a medical agreement with India, Malaysia, and Seoul St. Mary's Hospital to cooperate in the treatment of overseas cancer patients.

High frequency hyperthermia therapy principle

The operating principle of REMISSION 1℃, which is used for cancer treatment using high-frequency hyperthermia, is surprisingly simple. When high frequency waves are passed through the human body, frictional heat is generated due to the rotation, collision, and distortion of ionic charges within the body's cells due to the intersection of + - charges. This is called deep heat, and when the temperature of the core of the human body rises due to friction, metabolism is activated by promoting blood circulation. The heat generated in this way improves the body's immunity and kills infected cells such as inflammation and viruses that are vulnerable to heat. In the process, cancer cells will be killed. That is the main principle of REMISSION 1℃, a high-frequency hyperthermia therapy device.

In addition, high-frequency hyperthermia therapy device is a medical device that relieves the patient's pain with very few side effects. The device has been approved as a cancer treatment medical device by the Ministry of Food and Drug Safety in 2015 and is being used to treat numerous cancer patients at home and abroad.

https://www.timsf.org/ivra  

You can apply for participation by scanning your cell phone camera in the QR code.

Cooperation 아디포랩스   

Source: REMISSION 1℃ hyperthermia cancer treatment case presentation that can open up a new horizon in cancer treatment < NEWS & EVENT < Text of article - Monthly CEO& (ceopartners.co.kr)